• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


M6-C Artificial Cervical Disc-Extended Follow-up

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P170036 / PAS001
Date Current Protocol Accepted 10/08/2020
Study Name M6-C Artificial Cervical Disc-Extended Follow-up
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description Objective: To evaluate the 10-year long-term safety and effectiveness of the M6-C™ Artificial Cervical Disc in subjects with symptomatic cervical radiculopathy with or without cord compression.

Design: A continuation of the Prospective, multi-center, concurrently controlled IDE Study population to evaluate the long-term safety and effectiveness of the M6-C™ Artificial Cervical Disc.
Study Population Description Treatment group: M6-C™ Artificial Cervical Disc
Control group: Anterior Cervical Discectomy and Fusion (ACDF)
Sample Size Expected 122 M6-C™ IDE subjects and 53 ACDF control subjects
Data Collection Safety Endpoints:
The evaluation of all adverse events including device related, device procedure related, and additional serious adverse events
Explant and histological analysis
Subsequent surgical interventions
Neurological function

Effectiveness Endpoints:
Neck Disability Index (NDI)
Neck and arm pain - Visual Analog Scale (VAS)
Patient Satisfaction
Quantitative and qualitative radiographic assessments. In addition to endpoints studied for the PMA, these assessments will be used to evaluate range of motion and adjacent segment degeneration.

Follow-up Visits and Length of Follow-up 10 years
Interim or Final Data Summary
Interim Safety Information No statistically-significant differences were detected between Investigational and Control groups for AEs or SAEs. After 3 months F/U, 90% or more of subjects have 15 or more point decrease in Neck Disability Score through 84 months F/U. Very similar results for subjects achieving at least 20 mm decrease in VAS for neck pain and Shoulder/Arm pain. Physical and mental SF-12 assessments better with M6-C than with ACDF by minimum 3.7
to maximum 17.5 through 84 months F/U.
Actual Number of Patients Enrolled 151
Actual Number of Sites Enrolled 20
Patient Follow-up Rate Acceptable
Study Strengths & Weaknesses Strengths: Collection of long-term outcome data of desired patient population, collection of explants for any device failures.
Weaknesses: Potential for loss at follow up.

M6-C Artificial Cervical Disc-Extended Follow-up Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6 month report 08/07/2019 07/30/2019  
1 year report 02/06/2020 01/31/2020 On Time
18 month report 08/06/2020 07/07/2020 On Time
2 year report 02/05/2021 02/09/2021 Overdue/Received
3 year report 02/05/2022 02/09/2022 Overdue/Received
4 year report 02/05/2023    
5 year report 02/05/2024    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources